Literature DB >> 9836380

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

K Yoshizaki1, N Nishimoto, M Mihara, T Kishimoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9836380     DOI： 10.1007/bf00832010

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  64 in total

1.  In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets.

Authors:  S Asano; A Okano; K Ozawa; T Nakahata; T Ishibashi; K Koike; H Kimura; Y Tanioka; A Shibuya; T Hirano
Journal:  Blood       Date:  1990-04-15       Impact factor: 22.113

2.  Elevation of serum interleukin 6 prior to acute phase proteins on the inflammation by surgical operation.

Authors:  N Nishimoto; K Yoshizaki; H Tagoh; M Monden; S Kishimoto; T Hirano; T Kishimoto
Journal:  Clin Immunol Immunopathol       Date:  1989-03

3.  Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis.

Authors:  T Hirano; T Matsuda; M Turner; N Miyasaka; G Buchan; B Tang; K Sato; M Shimizu; R Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

4.  Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1.

Authors:  E R Stanley; A Bartocci; D Patinkin; M Rosendaal; T R Bradley
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

5.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

6.  Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.

Authors:  G V Campion; M E Lebsack; J Lookabaugh; G Gordon; M Catalano
Journal:  Arthritis Rheum       Date:  1996-07

7.  Involvement of IL-6 in mesangial proliferative glomerulonephritis.

Authors:  Y Horii; A Muraguchi; M Iwano; T Matsuda; T Hirayama; H Yamada; Y Fujii; K Dohi; H Ishikawa; Y Ohmoto
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

8.  Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells.

Authors:  T Andus; T Geiger; T Hirano; H Northoff; U Ganter; J Bauer; T Kishimoto; P C Heinrich
Journal:  FEBS Lett       Date:  1987-08-31       Impact factor: 4.124

9.  Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery.

Authors:  H Ohzato; K Yoshizaki; N Nishimoto; A Ogata; H Tagoh; M Monden; M Gotoh; T Kishimoto; T Mori
Journal:  Surgery       Date:  1992-02       Impact factor: 3.982

10.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

Authors:  P H Wooley; J Dutcher; M B Widmer; S Gillis
Journal:  J Immunol       Date:  1993-12-01       Impact factor: 5.422
View more
  33 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression.

Authors:  Shuzo Sato; Mara Lennard Richard; Danielle Brandon; Joy N Jones Buie; Jim C Oates; Gary S Gilkeson; Xian K Zhang
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

3.  2-Chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling.

Authors:  Masahiro Koshiba; Hidekazu Kosaka; Takashi Nakazawa; Nobuhide Hayashi; Ryuichi Saura; Noriko Kitamura; Shunichi Kumagai
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis.

Authors:  T Shouda; T Yoshida; T Hanada; T Wakioka; M Oishi; K Miyoshi; S Komiya; K Kosai; Y Hanakawa; K Hashimoto; K Nagata; A Yoshimura
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

Review 5.  Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Authors:  N Nishimoto; T Kishimoto; K Yoshizaki
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

6.  Evaluation of the anti-arthritic activity of the hydroethanolic leaf extract of Alchornea cordifolia in rats.

Authors:  Adejuwon Adewale Adeneye; Adekunle Ibrahim Oreagba; Ismail Ogunbayode Ishola; Hassanat Adeola Kalejaiye
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-01-28

Review 7.  Biologic agents in experimental autoimmune uveitis.

Authors:  Gian Paolo Giuliari; Ama Sadaka; David M Hinkle
Journal:  Int Ophthalmol       Date:  2013-03-14       Impact factor: 2.031

Review 8.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

9.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

10.  Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF-kappaB: a study on induced arthritis in rats.

Authors:  Cheng Xiao; Jing Zhou; Yinghui He; Hongwei Jia; Linhua Zhao; Ning Zhao; Aiping Lu
Journal:  Chin Med       Date:  2009-07-02       Impact factor: 5.455
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.